a Blue chip investor and micro cap trader.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
False & Misleading, Guy:
https://leadstories.com/hoax-alert/2020/12/fact-check-head-of-pfizer-research-did-not-say-covid-vaccine-is-female-sterilization.html
I have sold most of my PFE recently, but did not resort to “clickbait” to make a buck. Perspective is our greatest asset; truth is still ascertainable.
HEPA CEO WSJ Profile:
https://www.wsj.com/market-data/quotes/HEPA/company-people/executive-profile/86146
He has acquired 25,000 shares yesterday?
OS are only 32 million?
CEO Foster directly “acquired” 25,000 HEPA shares
yesterday at $1.57, 12/08/20.
MERRY CHRISTMAS?
http://archive.fast-edgar.com/20201208/ARB2V22D8W22W2Z222282CZZTQPVH2U2X222/
Nice 10% gain yesterday,
and on heavy volume.
This company may yet have a pulse. Big D virus not always fatal?
Dr. Robinhood to the rescue?
Right, from 11/25/20 RDHL SEC filing:
“...Enrollment in the 270-patient global Phase 2/3 study with opaganib in patients with severe COVID-19 pneumonia (NCT04467840) is more than 50% complete. The study is approved in six countries and is on track to deliver top-line data in the first quarter of 2021. This study is focused on and powered for efficacy evaluation, and recently received a unanimous recommendation to continue by an independent Data and Safety Monitoring Board (DSMB), following a pre-scheduled safety review of the first 70 patients to have been treated for 14 days. A prescheduled, unblinded futility interim analysis will also be conducted by the DSMB in the coming weeks, evaluating data from the first 135 subjects that have reached the primary endpoint...”
The RDHL PRESS RELEASE HAD THIS LANGUAGE FOLLOWING THE PARAGRAPH ABOVE FROM SEC 6k:
“...The parallel U.S. Phase 2 study with opaganib (NCT04414618) has completed enrollment of all 40 subjects, with topline data expected in the coming weeks. This study is not powered for efficacy and is focused on safety evaluation and identification of efficacy signals...”
So, RDHL MAY HAVE AMMO FOR A BLOCKBUSTER PR THE WEEK OF DECEMBER 7th.
BTW, “Remember Pearl Harbor!”
THE CLOCK IS TICKING
on the results of this news that came out about three weeks ago (11/17/20):
“ RedHill Biopharma Ltd. (RDHL Quick QuoteRDHL - Free Report) announced that it has completed enrollment in the phase II study on opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia. Top-line data from the study are expected in the coming weeks...”
Bonus: Stroke prevention:
Hepion Pharmaceuticals (NASDAQ:HEPA) has announced results from a translational research study in which its lead drug candidate, CRV431 decreased formation of a class of blood platelets, called ‘procoagulant platelets, and high levels of such platelets are associated with transient ischemic attack and stroke. (Dec. 02, 2020 8:37 AM ETHepion Pharmaceuticals, Inc. (HEPA)By: Meghavi Singh, SA News Editor)
Non-Bonus: Big D = Share Dilution, but not as bad as many penny stocks.
RDHL Analyst price target: $21.40 pps
(Based on proprietary 5 analyst ratings researched.
“I could show up, but then I would have to kill you” - Top Gun Movie quote about “Classified Material” .
But there is also this one not classified:
$19.00
(120.16% Upside)
2020
April
July
October
$10
$13
$16
$19
$22
? Past 12 Months
Next 12 Months ?
Based on 3 ranked analysts offering 12 month price targets for RDHL in the last 3 months.
The average price target is $19.00 with a high
Maybe he meant this conference today- it has a published slide show of interest,
TEL AVIV, Israel and RALEIGH, N.C., Nov. 23, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (RDHL) (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present and participate at the following virtual conferences in December:
https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg
Evercore ISI 3rd Annual HealthCONx Conference
Fireside chat and an open Q&A: Thursday, December 3, 2020, 8 a.m. EST
Moderator: Umer Raffat, Equity Research – Biotech-large, Pharma-major, Specialty Pharma
Speaker: Dror Ben-Asher, CEO & Gilead Raday, Chief Operating Officer
Piper Sandler 32nd Annual Virtual Healthcare Conference
Fireside chat: Available on-demand from November 23, 2020
Moderator: David Amsellem, Managing Director, Sr. Research Analyst, Specialty Pharma
Speaker: Guy Goldberg, Chief Business Officer
The webcasts will be available for replay for 30 days on the Company's website: https://
SLIDESHOW:
https://seekingalpha.com/article/4392829-redhill-biopharma-rdhl-investor-presentation-slideshow
RedHill has a COVID treatment blockbuster
...in the works. I suspect it will win emergency approval for use internationally in the very near future...3 or 4 weeks? I am loading the truck with shares-long!
Management is very talented and experienced in this pivot to Covid demand and political motivation for approval. This set up is very unusual as the CEO of SP said recently in a media interview: (Link discussing fast approval of PFE Vaccine: https://www.msn.com/en-us/news/us/its-unusual-for-countries-to-compete-for-approving-drugs-the-fda-isnt-far-behind-fmr-schering-plough-ceo/vp-BB1bzCzH )
I expect much more excitement here soon enough!!!
Lives and fortunes are at stake in this bloody pandemic...governments are looking for all the help they can get ASAP.
If so, where is the “pump”?
Where are the unsubstantiated company press releases, reflecting the pump?
I just this week flipped thousands of .08 cent warrants (CLRBZ) for over .27 cents...3 baggers are profitable!
You make a few good points, but trading volatility is just dating, not marriage!
CLRB is UP AGAIN this Wednesday in Pre-market trading,
and on over 100,000 shares traded.
CLRBZ is up again about 20% in pre-market after CLRBZ warrants were up 95% yesterday in day sesion!
WHERE IS THE PAID “boy who cried wolf”? Son of a gun is MIA...
I like the $1.77 high today!
...And on better volume of a few hundred thousand shares!
I assume a 20 odd percent gain for CLRB AT CLOSE AND A 95% gain on CLRBZ warrants was result of inside info leaking on clinical trial data...
Man with the Midas touch:
“Emergency use authorization applications planned as early as Q1/2021” will be approved by US FDA, JUST LIKE TODAY’s PFE application will be on its mRNA vaccine...Only the sooner the better! Right?
One golden difference between the two: PFE has a billion plus common shares outstanding; RDHL only a few million common shares outstanding.
Share architecture counts to investors/traders !
Analysts average target: $21.20
Why not: RDHL IS UP 18% in last 24 hours?
COVID, COVID, COVID-19....
What a big winner this company will be,
My Q1 2021 target is $2.75+ pps, based upon clinical trial news on MM and specific pediatric cancer applications with FDA emergency approvals for both. Good for patients and good for CLRB revenue; win/win!
I like the setup here,
...This company is one that I already own and am waiting to buy more on any dip in price.
Research is positive and share structure is attractive. Management is top drawer. News on clinical trials re Covid is trending.
WHAT MORE COULD I WANT? I like the setup for a spike up.
CLRBZ: up over 700%
On heavy volume of over 800,000 warrants traded.
INSIDE INFORMATION??? No public news yet?
THIS PRICE ACTION FOR CLRBZ SEEMS TOO DELAYED TO BE RELATED TO ORR NEWS.
WHAT COULD THE INSIDE INFORMATION BE HERE???
What’s up here, traders?
CLRBZ (warrants) are up over 50% today on the heaviest volume in months for those warrants @ .17?
Why accumulate this POS? Unless, ....Naaaaa...CLR131 can be monetized for doing good in the real world for very sick MM patients!!!
What’s up here, traders?
CLRBZ (warrants) are up over 50% today on the heaviest volume in months for those warrants @ .17?
Why accumulate this POS? Unless, ....Naaaaa...CLR131 can be monetized for doing good in the real world for very sick MM patients!!!
$5 Clover study of CLR131?
SonofGun!
Before the well is poisoned more
by resident bears, consider this Seeking Alpha article about biotech companies capitalizing their developments. The story is NOT finished here even if short bears will not go away and stop saving us from ourselves.
Expected capital raises continue to ramp in healthcare amid pandemic
May 09, 2020 12:40 PM ETCheck-Cap Ltd. (CHEK)2 Comments
The need for capital continues apace for healthcare companies as they deal with COVID-19 disruptions.
Stock offerings:
Check-Cap (NASDAQ:CHEK): direct placement of 5M ordinary shares at $0.60 per share plus 5 1/2-year warrants to purchase up to 5M shares at $0.80. Friday's close was $0.54.
Cellectar Biosciences (NASDAQ:CLRB): $17.5M public offering of stock and five-year warrants.
Mixed shelf filings:
BioTelemetry (NASDAQ:BEAT): unspecified.
Clearside Biomedical (NASDAQ:CLSD): $250M.
Arcturus Therapeutics (NASDAQ:ARCT): $200M.
Mersana Therapeutics (NASDAQ:MRSN): $250M.
CLRB’s DILUTION IS HUNDREDS OF TIMES SMALLER THAN THOSE OTHERS LISTED.
The real issue is a cure; no the cost of getting there!
BAD NEWS COMING NEXT HOUR:
I am outta here.
Wolf, takes over as your cheerleader.
Crusader OUT!
BAD NEWS COMING NEXT HOUR:
I am outta here.
Wolf, takes over as your cheerleader.
Crusader OUT!
Bingo !
$3.04 printed...thank you to Art Cashin @ UBS.
$3 price per share? Accumulation!
If so, the new screen names will show up here in this ghost town, and I will stop talking to myself and Wolf.
One last important point, cheap leverage in CLRB is available now in warrants: CLRBZ, currently selling at 10 cents per warrant that expire in April 2021. Could be a quick one or two bagger next week, or not. LOL
UBS Switzerland buying CLRB:
http://archive.fast-edgar.com//20200211/A32ZE22CZW2RJJZ222262ZYRT5J3ZZ223I22/
6 more days to wait for fog to clear:
Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020
BY GlobeNewswire
— 8:00 AM ET 01/09/2020
FLORHAM PARK, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences ( CLRB
Cellectar Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it will host a Clinical Data Call on Wednesday, February 19, 2020 at 10:30 am Eastern Time.
Members of Cellectar’s senior management team and Dr. Sikander Ailawadhi, M.D., the lead investigator for the company’s Phase 2 study, will provide additional clinical data, as well as an update and analysis of the CLR 131 Phase 1 and Phase 2 hematology focused trials. The team will also provide a summary of the data for patients with relapsed/refractory B-cell malignancies, including patients with multiple myeloma and select non-Hodgkins lymphoma. Additionally, the team will review the current treatment landscape and unmet medical need for treating patients with these cancers, and provide an overview of the market opportunity and its clinical development plan for CLR 131.
Sikander Ailawadhi, M.D. is an Associate Professor, Division of Hematology/Oncology at Mayo Clinic Florida and is the lead investigator for the company’s Phase 2 CLOVER-1 trial of CLR 131 in patients with relapsed/refractory B-cell hematologic cancers. Dr. Ailawadhi was awarded the 2013 NCI CCITLA as an Assistant Professor of Medicine at the Norris Cancer Center, University of Southern California (USC), Los Angeles CA. Subsequently, he joined the Division of Hematology and Oncology at Mayo Clinic in Florida as a Senior Associate Consultant in order to pursue his career goal of clinical, translational and outcomes-based research in B-cell malignancies, especially plasma cell disorders.
X$2.80 close after hours market 2/4/20...
TENB Accumulation even after smart acquisition of OT company: INDEGY.
NOW THIS INSTITUTIONAL INVESTOR likes the TENB future.
Columbine Capital Services, Inc. upgrades TENABLE HOLDINGS INC from 3 to 2.
BY Investars Analyst Actions - private
— 2:20 PM ET 01/25/2020
On January 25, 2020 Columbine Capital Services, Inc. upgraded TENABLE HOLDINGS INC from 3 to 2.
TENB Accumulation even after smart acquisition of OT company:
Columbine Capital Services, Inc. upgrades TENABLE HOLDINGS INC from 3 to 2.
BY Investars Analyst Actions - private
— 2:20 PM ET 01/25/2020
On January 25, 2020 Columbine Capital Services, Inc. upgraded TENABLE HOLDINGS INC from 3 to 2.
$2.78 morning high; who is accumulating here?
Could it be some of these smart money folks or some retail investors other than Sunofwolf.
There was a single 10,000 share purchase of CLRB IN THE OPENING HOUR OF TRADING TODAY.
Cellectar BioSciences Inc, Inst Holders, 4Q 2019 (CLRB)
BY Dow Jones & Company, Inc.
— 3:50 AM ET 01/22/2020
The following table shows the largest shareholders in CELLECTAR BIOSCIENCES INC COM (CLRB) for the quarter ended December 31, 2019, listed by holding size. The list represents up to 50 of the largest holders in the company.
Note: Unless otherwise mentioned the reporting date is 12/31/2019
Institution Shares Shares % Last
Held Changed Held Report
Tavistock Life Sciences Co. (I 920,000 0 9.791 09/30
Tang Capital Management LLC 235,701 (444,299) 2.509 09/30
Renaissance Technologies LLC 176,902 53,854 1.883 09/30
Sphera Funds Management Ltd. 87,500 0 0.931 09/30
Morgan Stanley Smith Barney LL 32,221 (3,000) 0.343 09/30
The Vanguard Group Inc. 16,755 0 0.178 09/30
Private Advisor Group LLC 13,400 0 0.143 09/30
JPMorgan Securities LLC (Inves 10,505 10,505 0.112 09/30
For cheap LEVERAGE: Remember CLRBZ
April 2021 Warrants currently trading at $.15 this am.
CLRBZ 52 week high near one dollar per. Leverage!
CLRBZ before 2-19-20 press release of more clinical trial data.
THERE MUST BE SOME INSIDER INFORMATION BEHIND THE RECENT CLRB ACCUMULATION!!!
CLRB TRADING AT $2.79 pps THIS MORNING, UP ALMOST 5 %
There's something happening here
What it is ain't exactly clear
There's a man with a gun over there
Telling me I got to beware
REMEMBER FEBRUARY 19, 2020 for more clinical trial data.
Happy Hour open price $2.75 pps,
Calmer heads prevailed on FDA orphan drug news this morning.
https://seekingalpha.com/news/3529761-cellectar-bio-up-11-premarket-on-orphan-drug-tag-for-clr-131-in-lpl?source=cnbc
WHere is the BOTTOM LINE of CLRB for MM patients:
Page 10 from the CLRB data presentation in my last post below.
It shows trial result numbers better than CAR-T trials and on-going CLR131 ORR as good and becoming better than MM drugs now being sold when they were at this stage of CLRB’s clinical trials- ON SEVERAL FORM OF CANCER, NOT JUST MM!
The FDA has approved many popular MM drugs such as Pomalyst which had an ORR of just 30% in its clinical trials. ( SEE PAGE 9 of presentation linked below) Now Pomalyst is selling at $17,000 for 21 4mg pills = one month dosing for use with Decadron once a week.
According to page 10 of the presentation ( https://seekingalpha.com/article/4316868-cellectar-biosciences-clrb-presents-biotech-showcase-2020-slideshow?dr=1&source=2800:read_now&utm_medium=email&utm_source=seeking_alpha ) CLR131 has already met and exceeded Pomalyst’s ORR IN CLINICAL TRIALS results (page 9) before Celegene was approved to market Pomalyst.
I BELIEVE CLRB WILL BE BOUGHT OUT (M&A) BY BIG PHARMA WITHIN ONE YEAR FOR REASONS REFLECTED IN LINK ABOVE OF CLRB’s PUBLIC PRESENTATION SCHEDULED FOR 2-19-20.
Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020
BY GlobeNewswire
— 8:00 AM ET 01/09/2020
FLORHAM PARK, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences ( CLRB
), Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it will host a Clinical Data Call on Wednesday, February 19, 2020 at 10:30 am Eastern Time.
WHY HIRE A CHIEF MEDICAL RESEARCH OFFICER
with experience in global drug approval processes? And then this stock goes up in price 10%, more or less and after an announcement of a CLR131 clinical data release is scheduled for 2-19-20?
Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer
BY GlobeNewswire
— 8:00 AM ET 01/07/2020
FLORHAM PARK, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. ( CLRB
CLRB, “...a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it has appointed Dr. Igor Grachev as Chief Medical Officer.
“I am excited to welcome Igor to our senior management team as Chief Medical Officer. Igor possesses outstanding academic training and a track record of professional success with highly relevant experiences including multiple global oncology drug approvals ,” said Jim Caruso, CEO of Cellectar. “We look forward to his leadership as we advance our pipeline of assets and work towards fully developing the potential of CLR 131.”
Igor Grachev, M.D., Ph.D., brings nearly 20 years of industry experience to Cellectar having led clinical development programs at both multinational pharmaceutical and biotech organizations. He served as Global Development Leader and Head of Innovative Clinical Trials Initiative, R&D for TEVA Branded Specialty Pharmaceuticals, where he was responsible for the development, execution and management of clinical programs worldwide across all phases of clinical research, achieving regulatory approvals in multiple countries. Dr. Grachev also had clinical development and medical affairs leadership roles at GE Healthcare, Novartis, GSK, Merck, Schering Plough, Sanofi-”
AND WHY GIVE HIM A 80,000 common shares stock option as shown in a subsequent SEC filing regarding a Power of Attorney filing for 4 people to make SEC Form 4 STOCK TRANSACTION notices for him?
SOMETHING IMPORTANT IS ABOUT TO HAPPEN, MAYBE NEXT SUNDAY?